Commercial strategy for Gilead's Covid-19 drug-to-be remdesivir remains opaque, as chief O'Day emphasizes responsibility - Endpoints News

Commercial strategy for Gilead's Covid-19 drug-to-be remdesivir remains opaque, as chief O'Day emphasizes responsibility  Endpoints News